The fact that the FDA is considering ending the trial early is a strong testament to the efficacy of BTM. Short term, this would likely provide a SP boost. Long term, it's an outstanding disruptive cost effective technology that will grow exponentially regardless of the trial completion date.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.010(0.85%) |
Mkt cap ! $804.8M | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.20 | $1.16 | $1.373M | 1.169M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 36326 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 31693 | 25 |
View Market Depth
| Last trade - 14.31pm 26/06/2025 (20 minute delay) ? |
| PNV (ASX) Chart |